Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

  • Awaiting development
  • GID-TA11743
  • Expected publication date: TBC
To appraise the clinical and cost effectiveness of Povorcitinib within its marketing authorisation for treating hidradenitis suppurativa ID6569